Interim report Q3, 2024: Improved growth with solid margins

Third quarter

• Sales of SEK 867 (848) million, an increase of 7% in local currencies and 2% in SEK.
• Sales per region, in local currencies was +9% in EMEA, +2% in Americas and +9% in APAC.
• Sales per business area, in local currencies was +13% in Consumables, +11% in Technologies and 0% in Genetics.
• Gross margin increased to 58.6% (55.7).
• Operating income before depreciation and amortisation (EBITDA) was SEK 289 (287) million, giving an EBITDA margin of 33.4% (33.9).
• Operating cash flow decreased to SEK 206 million (214).
• Net income was SEK 116 (122) million, resulting in earnings per share of SEK 0.85 (0.90).

First nine months

• Sales of SEK 2,650 (2,607) million, an increase of 4% in local currencies and 2% in SEK.
• Sales per region, in local currencies was +6% in EMEA, -2% in Americas and +7% in APAC.
• Sales per business area, in local currencies was +10% in Consumables, +20% in Technologies and -7% in Genetics.
• Gross margin increased to 58.6% (56.1).
• Operating income before depreciation and amortisation (EBITDA) increased to SEK 888 (842) million, giving an EBITDA margin of 33.5% (32.3).
• Operating cash flow increased to SEK 640 million (586).
• Net income was SEK 375 (328) million, resulting in earnings per share of SEK 2.76 (2.42).
  

Gothenburg, October 24, 2024
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO

The information was submitted for publication, through the agency of the contact persons set out above, at 24-10-2024 08:00 CET.

Contact:
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.